Sanofi said it entered an agreement to acquire Vigil Neuroscience for approximately $470 million, a deal that adds a new investigational treatment for Alzheimer's disease to the French pharmaceutical ...

Now, scientists and other bright minds have put forth a few different timelines as to when they believe AGI will be developed, and become mainstream. For example… Leopold Aschenbrenner, a ...

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 Danish kroner ($58 ...

All medications are managed by the InnovAge teams, pre-packaged in daily doses, sent to enrolled seniors’ homes, and continuously monitored. This can result in seniors taking fewer medications and ...

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...

"We are excited to be entering into this collaboration with Synfini to accelerate drug discovery around a publicly available high-value target,” said Helena Mancebo, CEO of Multispan. "By using ...

The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...

The president announced last week that his administration would be instituting a “most favored nation” policy that would peg ...

Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way ...

3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving ...